Is Cue Biopharma, Inc. CUE stock halal to invest in?

Yes, as of August 2026, Cue Biopharma, Inc. stock (CUE) is classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening halal stocks. Cue Biopharma, Inc. currently passes all four AAOIFI financial screens: non-permissible income remains below 5% of total revenue, interest-bearing investments and interest-bearing debt each remain below 30% of market capitalisation, and the company has no impermissible preference share structure. The stock's current purification factor is 96.95%. Compliance is reassessed every month as updated screening data arrives, and a stock's status can change when new financial reports are released. You can always check the current status of Cue Biopharma, Inc. and explore other Shariah compliant stocks in the Tabadulat app.

How often is Cue Biopharma, Inc. CUE reviewed for Shariah compliance?

Tabadulat reviews Cue Biopharma, Inc. CUE for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Cue Biopharma, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Cue Biopharma, Inc. CUE pass the AAOIFI Non Permissible Income criteria?

Yes, as of August 2026, Cue Biopharma, Inc. stock (CUE) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Cue Biopharma, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Cue Biopharma, Inc. CUE pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of August 2026, Cue Biopharma, Inc. stock (CUE) passes the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. This limit ensures shareholders are not materially profiting from riba (interest). Cue Biopharma, Inc.'s interest-bearing investments are currently within the 30% threshold. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Cue Biopharma, Inc. CUE pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of August 2026, Cue Biopharma, Inc. stock (CUE) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Cue Biopharma, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Cue Biopharma, Inc. CUE stock?

As of August 2026, the dividend purification factor for Cue Biopharma, Inc. (CUE) is 96.95%. Purification (tazkiyah) is the practice of donating to charity the portion of dividend income attributable to incidental non-permissible sources, typically interest earned on a company's cash, and AAOIFI methodology requires it even for fully compliant stocks. The purification factor is the figure halal investors use to work out that donation on Cue Biopharma, Inc. dividends. It is recalculated with each monthly screening as new financial data arrives, and the Tabadulat app can help you calculate and track purification across your whole portfolio.

Does Cue Biopharma, Inc. CUE pass the AAOIFI Preference Share screen?

Yes, as of August 2026, Cue Biopharma, Inc. stock (CUE) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Cue Biopharma, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Cue Biopharma, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

CUE

About

Cue Biopharma, Inc.

CUE

Cue Biopharma Inc. is a biotechnology company focused on developing innovative biologic drugs that can precisely modulate the human immune system. The company's primary purpose is to create therapies that can selectively enhance or inhibit immune responses, potentially leading to treatments for a wide array of diseases, including cancer and autoimmune disorders. A notable feature of Cue Biopharma is its proprietary drug development platform, Immuno-STAT, designed to target specific T cells in the immune system, thereby refining the activation or suppression of immune processes. This targeted approach could impact several sectors, particularly oncology and immunotherapy, by offering more targeted and potentially effective treatment options. Founded in 2014 and based in Massachusetts, Cue Biopharma is a key player in the biotechnology industry, contributing to the growing body of research and development in precision medicine. Its work has significant market implications, as the demand for personalized medicine and immunotherapies continues to rise, reflecting broader trends in healthcare innovation and therapeutic development.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

Website:

https://www.cuebiopharma.com

CUE

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Cue Biopharma, Inc.

About

Cue Biopharma, Inc.

CUE

Frequently asked questions

Is Cue Biopharma, Inc. CUE stock halal to invest in?

How often is Cue Biopharma, Inc. CUE reviewed for Shariah compliance?

Does Cue Biopharma, Inc. CUE pass the AAOIFI Non Permissible Income criteria?

Does Cue Biopharma, Inc. CUE pass the AAOIFI Interest Bearing Investments criteria?

Does Cue Biopharma, Inc. CUE pass the AAOIFI Interest Bearing Debt criteria?

What is the dividend purification factor for Cue Biopharma, Inc. CUE stock?

Does Cue Biopharma, Inc. CUE pass the AAOIFI Preference Share screen?

How do I buy Cue Biopharma (CUE) stock?

Open your account.

Deposit.

Screen.